Similar articles

• Targeting blood-brain barrier sphingolipid signaling reduces basal P-glycoprotein activity and improves drug delivery to the brain.

  Cannon RE, Peart JC, Hawkins BT, Campos CR, Miller DS. Cannon RE, et al. Proc Natl Acad Sci U S A. 2012 Sep 25;109(39):15930-5. doi: 10.1073/pnas.1203534109. Epub 2012 Sep 4. Proc Natl Acad Sci U S A. 2012. PMID: 22949658 Free PMC article.
• [Sphingosine-1-phosphate signaling system and the innovative mechanism of action of fingolimod in treatment of multiple sclerosis: review of foreign literature].

  Shmyrev VI, Kryzhanovskiĭ SM, Danilycheva IV. Shmyrev VI, et al. Zh Nevrol Psikhiatr Im S S Korsakova. 2012;112(2 Pt 2):93-7. Zh Nevrol Psikhiatr Im S S Korsakova. 2012. PMID: 22677684 Review. Russian.
• Activation of sphingosine 1-phosphate receptor-1 by FTY720 is neuroprotective after ischemic stroke in rats.

  Hasegawa Y, Suzuki H, Sozen T, Rolland W, Zhang JH. Hasegawa Y, et al. Stroke. 2010 Feb;41(2):368-74. doi: 10.1161/STROKEAHA.109.568899. Epub 2009 Nov 25. Stroke. 2010. PMID: 19940275 Free PMC article.
• Mrp1 is essential for sphingolipid signaling to p-glycoprotein in mouse blood-brain and blood-spinal cord barriers.

  Cartwright TA, Campos CR, Cannon RE, Miller DS. Cartwright TA, et al. J Cereb Blood Flow Metab. 2013 Mar;33(3):381-8. doi: 10.1038/jcbfm.2012.174. Epub 2012 Nov 21. J Cereb Blood Flow Metab. 2013. PMID: 23168528 Free PMC article.
• Central effects of fingolimod.

  Cruz VT, Fonseca J. Cruz VT, et al. Rev Neurol. 2014 Aug 1;59(3):121-8. Rev Neurol. 2014. PMID: 25030072 Review. English, Spanish.